Lineage Cell Therapeutics Inc Webinar Featuring External Therapeutic Area Experts Transcript
Good afternoon, everyone. My name is Brian Culley. I'm the Chief Executive Officer of Lineage Cell Therapeutics. I'd like to welcome you to a very special webinar today.
Before I begin, I'll refer you all to our safe harbor clause as I or other Lineage executives may make some forward-looking statements today, and you can learn more about our risk factors through our filings with the Securities and Exchange Commission at sec.gov.
Now I know many of you were expecting us to report our 6-month interim data for OpRegen, but we've moved that update to next month in order to make room for something far more exciting. As you all know, we have reported that an earlier observation of retinal tissue restoration has been repeated in 2 additional patients on the OpRegen clinical trial. So we believe this is much more than just an exciting clinical observation for these 3 individuals. We believe this first-of-its-kind data using a replace-and-restore approach represents a new paradigm for how the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
